AstraZeneca

News

AstraZeneca prepares to move its oral GLP-1 elecoglipron into phase 3 for obesity and diabetes, after reporting encouraging phase 2b data at ADA.

News

AstraZeneca showcases new data from the SERENA-6 data of camizestrant in breast cancer that it hopes will get FDA's review of the drug back on track.

News

EMERALD-3 suggests a triplet regimen based on AstraZeneca's Imfinzi and Imjudo could be practice-changing as a frontline hepatocellular carcinoma.

News

Trials of AstraZeneca's anselamimab and Regeneron's Lynozyfic could deliver much-needed new therapeutic options for rare disease AL amyloidosis.

News

AstraZeneca has claimed another key FDA approval for Imfinzi in bladder cancer, as an add-on to BCG therapy for early non-muscle invasive disease.

News

After an advisory committee setback, AstraZeneca has a chance to make the case for its oral SERD camizestrant for breast cancer.